Group 1: IPO Activities - The first trading week of 2026 saw significant IPO activities in both domestic and international capital markets, marking an active start to the year [2] - The Beijing Stock Exchange approved its first IPO of the year, with Zhoushan Chenguang Electric Motor Co., Ltd. successfully passing the review [2] - Hong Kong's stock market experienced a surge of hard-tech company listings, with companies like Zhipu, Tensu Zhixin, and Jingfeng Medical showing strong performance despite market adjustments [2][5] Group 2: Company Highlights - Zhoushan Chenguang Electric Motor Co., Ltd. plans to raise 399 million yuan, down from an initially proposed 520 million yuan, with funds allocated for high-speed motors and R&D center construction [3] - Guangdong Banzai Chuangke Electric Co., Ltd. aims to raise approximately 400 million yuan, showing significant revenue growth from 10.71 billion yuan in 2022 to an expected 15.1 billion yuan in 2025 [4] - Zhipu, listed on the Hong Kong Stock Exchange, had an opening price of 116.2 HKD, closing at 131.5 HKD, with a total market value of 57.89 billion HKD and a fundraising total of about 4.348 billion HKD [5] - Tensu Zhixin, another new listing, opened at 190.2 HKD, closing at 156.8 HKD, with a total market value of 39.877 billion HKD and raising approximately 3.677 billion HKD [5] - Jingfeng Medical-B, a leader in surgical robotics, saw its stock rise to 56.6 HKD from an initial price of 43.24 HKD, achieving a market value of 21.945 billion HKD and raising about 1.199 billion HKD [6] Group 3: Upcoming IPOs and Filings - Stand Robot and Wanbang Digital Energy have submitted their IPO applications, with Stand Robot being a leader in industrial mobile robot solutions and Wanbang being the largest smart charging equipment supplier globally [8] - Other companies like Tianxiaxiu and Zhong'an Xinke are also in the process of filing for IPOs, focusing on digital marketing and customized AI solutions respectively [9][10] - Chipmaker Xinmai Semiconductor updated its prospectus for a second time, focusing on power management ICs and reporting a revenue increase of 24.3% for the first three quarters of 2025 [10]

"手术机器人的终局是智能化" 精锋医疗上市，为祥峰投资在机器人赛道再添重要IPO案例。谈及祥峰投资在精锋医疗发展过程中的角 色，刘天然定位为"共创者"。"在关键节点，我们协助企业聚焦战略、引入淡马锡等全球顶级资本。"她 认为，资本最大的价值，是助力技术成果更好地落地转化。 回顾其融资历程，2018年，精锋医疗A轮融资吸引了中恒汇金、广远众合、嘉兴繸子等多家机构；2020 年，联想之星、国策资本等现身其Pre-B轮融资；2021年，精锋医疗B轮融资超过5亿元，投资机构包括 红杉中国、淡马锡、博裕资本、祥峰投资、国策投资、三正健康等；2021年的交叉轮融资中，社保基 金、中国国企混改基金、OrbiMed、LYFE Capital、祥峰投资等均现身，融资额超2亿美元，估值超15亿 美元。 精锋医疗是祥峰投资合伙人刘天然在香港的第三个IPO项目。2020年，国内手术机器人行业初露锋芒， 精锋医疗刚步入临床阶段。彼时行业热度渐起，但刘天然和团队并未急于出手，而是深入手术室、与医 生访谈、分析患者数据，持续追踪验证团队执行力、产品落地能力、与医生的配合度等指标，串联技 术、临床、政策等全要素判断项目潜力。 最终，刘天然被 ...